EyePoint Pharmaceuticals Inc (EYPT)
11.59
-0.49
(-4.06%)
USD |
NASDAQ |
Nov 07, 16:00
11.59
0.00 (0.00%)
Pre-Market: 08:39
EyePoint Pharmaceuticals Revenue (TTM): 50.39M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 50.39M |
| March 31, 2024 | 50.02M |
| December 31, 2023 | 46.02M |
| September 30, 2023 | 42.52M |
| June 30, 2023 | 37.33M |
| March 31, 2023 | 39.79M |
| December 31, 2022 | 41.40M |
| September 30, 2022 | 42.42M |
| June 30, 2022 | 41.46M |
| March 31, 2022 | 38.91M |
| December 31, 2021 | 36.94M |
| September 30, 2021 | 32.53M |
| June 30, 2021 | 39.16M |
| March 31, 2021 | 34.27M |
| December 31, 2020 | 34.44M |
| September 30, 2020 | 35.94M |
| June 30, 2020 | 22.75M |
| March 31, 2020 | 25.84M |
| December 31, 2019 | 20.36M |
| September 30, 2019 | 12.22M |
| June 30, 2019 | 10.42M |
| March 31, 2019 | 4.141M |
| September 30, 2018 | 3.062M |
| June 30, 2018 | 2.961M |
| March 31, 2018 | 2.947M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.609M |
| September 30, 2017 | 7.647M |
| June 30, 2017 | 7.539M |
| March 31, 2017 | 7.142M |
| December 31, 2016 | 6.876M |
| September 30, 2016 | 1.431M |
| June 30, 2016 | 1.62M |
| March 31, 2016 | 1.725M |
| December 31, 2015 | 1.729M |
| September 30, 2015 | 1.724M |
| June 30, 2015 | 26.56M |
| March 31, 2015 | 26.45M |
| December 31, 2014 | 28.11M |
| September 30, 2014 | 28.18M |
| June 30, 2014 | 3.473M |
| March 31, 2014 | 3.673M |
| December 31, 2013 | 2.194M |
| September 30, 2013 | 2.187M |
| June 30, 2013 | 2.143M |
| March 31, 2013 | 2.35M |
| December 31, 2012 | 2.375M |
| September 30, 2012 | 2.42M |
| June 30, 2012 | 3.526M |
| March 31, 2012 | 6.542M |
| December 31, 2011 | 6.364M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
20.36M
Minimum
Dec 2019
50.39M
Maximum
Jun 2024
37.50M
Average
38.91M
Median
Mar 2022
Revenue (TTM) Benchmarks
| Cassava Sciences Inc | -- |
| Adverum Biotechnologies Inc | -- |
| Regenxbio Inc | 84.33M |
| Editas Medicine Inc | 61.76M |
| Apellis Pharmaceuticals Inc | 715.22M |